Kezar scarred as midphase autoimmune blowup raises doubts about pipeline-in-a-drug visionnews2022-05-04T13:28:16+00:00May 4th, 2022|FierceBiotech|
Catalio reloads with $381M after financing Octant, Pheastnews2022-05-04T13:23:18+00:00May 4th, 2022|FierceBiotech|
Biogen shoves Aduhelm to the side. It’s time for lecanemabnews2022-05-04T12:22:42+00:00May 4th, 2022|FierceBiotech|
Chasing Bristol Myers and Pfizer, Connect fails phase 2 ulcerative colitis trial but spies path forwardnews2022-05-04T11:54:41+00:00May 4th, 2022|FierceBiotech|
BMS, Merck KGaA push protein degrader ambitions with $2.3B Amphista partnershipsnews2022-05-03T22:38:33+00:00May 3rd, 2022|FierceBiotech|
Record-breaking 2021 revenue shows there’s more to Swiss biotech sector than Roche, Novartisnews2022-05-03T18:22:12+00:00May 3rd, 2022|FierceBiotech|
Another Pfizer gene therapy is free of FDA hold, but delay continuesnews2022-05-03T15:00:54+00:00May 3rd, 2022|FierceBiotech|
Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drugnews2022-05-03T14:40:12+00:00May 3rd, 2022|FierceBiotech|
After a dismal last year, Sesen Bio grasps for alternatives to stay afloatnews2022-05-03T14:18:01+00:00May 3rd, 2022|FierceBiotech|
Sierra wanted a partnership, but GSK wanted the store: How the $1.9B buyout came to benews2022-05-03T14:04:56+00:00May 3rd, 2022|FierceBiotech|
